“Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL,” by Jennifer A. Woyach, Amy S. Ruppert, Nyla A. Heerema, Weiqiang Zhao, Allison M. Booth, Wei Ding, Nancy L. Bartlett, Danielle M. Brander, Paul M. Barr, Kerry A. Rogers, Sameer A. Parikh, Steven Coutre, Arti Hurria, Jennifer R. Brown, Gerard Lozanski, James S. Blachly, Hatice G. Ozer, Brittny Major-Elechi, Briant Fruth, Sreenivasa Nattam, Richard A. Larson, Harry Erba, Mark Litzow, Carolyn Owen,Charles Kuzma, Jeremy S. Abramson, Richard F. Little, Scott E. Smith, Richard M. Stone, Sumithra J. Mandrekar, and John C. Byrd (Vol. 379, No. 26, December 27, 2018, p. 2517-2528).
December 28, 2018
CAAR – New England Journal of Medicine Article Abstract – December 28, 2018
Comments Off on CAAR – New England Journal of Medicine Article Abstract – December 28, 2018
January 6, 2014
CAAR – Lancet Oncology Article Abstract – January 6, 2014
Note: Lancet requires free registration prior to providing access. “Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial,” by Susan O’Brien, Richard R. Furman, Steven E. Coutre, Jeff P. Sharman, Jan A. Burger, Kristie A. Blum, Barbara Grant, Donald A. Richards, Morton Coleman, William G. Wierda, Jeffrey A. Jones, Weiqiang Zhao, Nyla A. Heerema, Amy J. Johnson, Raquel Izumi, Ahmed Hamdy, Betty Y. Chang, Thorsten Graef, Fong Clow, Joseph J. Buggy, Danelle F. James, and John C. Byrd (Vol. 15, No. 1, January 2014, p. 48-58).
www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70513-8/abstract
Comments Off on CAAR – Lancet Oncology Article Abstract – January 6, 2014
